PaclitaxelRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2026
- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Paclitaxel” · registered May 2026
- NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2025
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 1113 studies | 1116 studies | comparator 14 · background 18 |
liposomal doxorubicinRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Oct 2026
- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jul 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered May 2026
- NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Apr 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Oct 2025
| Johnson & Johnson21% of its industry studiesEU: Baxter Healthcare Corporation (EMA 1996) + 2 others | 1011 studies | 89 studies | comparator 11 · background 6 |
BevacizumabRecent, repeatedEvidence- NCT07859215 · Genmab · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07851025 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07816666 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07811271 · BeOne Medicines · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07776691 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 915 studies | 916 studies | background 18 · comparator 2 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Jul 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Carboplatin” · registered Oct 2025
- NCT07024784 · AbbVie · Phase 2 · live · background · “Carboplatin” · registered Jun 2025
- NCT06915025 · Imunon · Phase 3 · live · background · “Carboplatin” · registered Apr 2025
- NCT06087289 · Kancera AB · Phase 2 · background · “Carboplatin” · registered Sep 2023
| Eli Lilly and Company16% of its industry studies | 89 studies | 811 studies | comparator 2 · background 21 |
TopotecanRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Oct 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Topotecan” · registered May 2026
- NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Apr 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Topotecan” · registered Oct 2025
- NCT06751485 · Alphamab Oncology · Phase 3 · live · comparator · “Topotecan” · registered Dec 2024
| GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized | 78 studies | 67 studies | comparator 10 |
GemcitabineRecent, repeatedEvidence- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered May 2026
- NCT06834672 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “paclitaxel/Gemcitabine/Liposomal doxorubicin” · registered Feb 2025
- NCT06619236 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered Sep 2024
- NCT05870748 · Sutro Biopharma, Inc. · Phase 3 · comparator · “Gemcitabine” · registered May 2023
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 45 studies | 45 studies | comparator 6 · background 3 |
niraparibRecent, repeatedEvidence- NCT06915025 · Imunon · Phase 3 · live · background · “Niraparib” · registered Apr 2025
- NCT05335993 · CanariaBio Inc. · Phase 2 · live · background · “Niraparib” · registered Feb 2022
- NCT05198804 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2 · background · “Niraparib” · registered Dec 2021
| GlaxoSmithKline53% of its industry studiesUS: GlaxoSmithKline (FDA 2023)EU: GlaxoSmithKline (EMA 2017) | 33 studies | 22 studies | background 3 |
olaparibRecent, repeatedEvidence- NCT07024784 · AbbVie · Phase 2 · live · background · “Olaparib” · registered Jun 2025
- NCT06915025 · Imunon · Phase 3 · live · background · “Olaparib” · registered Apr 2025
| AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014) | 22 studies | 22 studies | background 2 |
pegfilgrastimRecent, repeatedEvidence- NCT06690775 · TORL Biotherapeutics, LLC · Phase 2 · live · background · “Pegfilgrastim (drug)” · registered Nov 2024
- NCT05870748 · Sutro Biopharma, Inc. · Phase 3 · background · “Pegfilgrastim” · registered May 2023
| Amgen29% of its industry studiesUS: Amgen (FDA 2002) + 7 othersEU: Amgen (EMA 2002) + 12 others | 22 studies | 11 study | background 2 |